Led · Series A · Apr 2026

SQUAREMIND develops an integrated dermatology platform combining robotics, high-resolution imaging and artificial intelligence to digitize and map the entire skin surface in minutes. Its flagship product, Swan™, automates image acquisition at dermoscopic resolution and pairs that capture with AI-assisted review and longitudinal lesion tracking. The company positions the technology to increase clinicians’ diagnostic throughput and to standardize documentation for follow-up and screening. SquareMind plans to industrialize production and expand commercial teams to deploy the platform across Europe and the United States. The startup raised $18 million in the current financing (including a prior pre-Series A) to fund these plans. It is led by cofounder and CEO Ali Khachlouf and was founded in Paris.

Participated · Series B · Mar 2026

Vitestro is a Netherlands-headquartered medical-robotics company focused on automating diagnostic blood draws with its Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™). The CE-marked system combines multimodal imaging, advanced robotics, and artificial intelligence to locate veins, guide needle insertion, and collect blood with high precision and consistency. By standardizing venous access, the platform aims to alleviate staffing shortages, reduce variability, and improve patient experience in high-volume outpatient environments. Vitestro is currently deploying Aletta® in clinical and pre-commercial sites across Europe while pursuing a U.S. FDA De Novo clearance. Proceeds from its latest financing will fund next-generation product development, manufacturing scale-up, additional clinical studies, and the build-out of global commercial infrastructure.

Led · Seed · Nov 2025

Cordance Medical is building a noninvasive focused ultrasound system designed to temporarily and safely open the blood-brain barrier (BBB), enabling drugs and other therapeutic agents to reach the brain more effectively. The platform employs patient-specific signal processing with real-time monitoring of BBB opening and avoids the need for head fixation or live imaging, targeting practical outpatient use. While its first clinical application is brain cancer, the company envisions broader utility across multiple neurological conditions. Cordance has already secured FDA Breakthrough Device Designation in neuro-oncology and received a grant from the National Cancer Institute at the NIH to help fund its first-in-human U.S. trial. Proceeds from its recent seed financing will advance this clinical study and further product development. Based in Mountain View, California, the firm is supported by a strong syndicate of healthcare and neuro-oncology investors. The company has not disclosed revenue, user numbers, or other operating metrics.

Led · Series B · Oct 2025

Jupiter Endovascular is creating a new class of endovascular procedures that use its proprietary Transforming Fixation (TFX) technology, which can flexibly navigate vasculature and then pressurize to stabilize at the treatment site. The technology is integrated into the company’s Vertex catheter system, which just received FDA 510(k) clearance. Initial clinical focus is pulmonary embolism: the SPIRARE I first-in-human study treated 10 intermediate-risk PE patients in Europe and results will be presented at TCT 2025, while the pivotal SPIRARE II trial is enrolling up to 145 patients across up to 25 U.S. and European sites. Beyond pulmonary embolism, Jupiter plans to extend TFX to additional high-need cardiovascular applications. Proceeds from its latest financing will fund completion of SPIRARE II, commercialization preparations, and pipeline expansion. The oversubscribed Series B, which exceeded its $40 million target, positions the company to advance toward market launch; no revenue or user figures have been disclosed.

Participated · Series D · Aug 2024

Neptune Medical develops advanced medical devices with a primary focus on gastrointestinal robotics. The company’s mission is to enhance patient outcomes through innovative technology and collaborative partnerships. Neptune recently completed a $97M Series D financing, which the company says will strengthen its focus on GI robotics and expansion into robotics for GI disease. Neptune appointed medical robotics pioneer Dr. Fred Moll as Chairman of the Board, underscoring its emphasis on medical-robotics expertise. The company also spun out its subsidiary, Jupiter Endovascular, enabling that business to concentrate on a novel endovascular technology platform. Jupiter Endovascular is developing a new class of endovascular procedures to bring the precision and control of direct surgical access to catheter-based interventions.